Stay updated on CTX001 in Severe Sickle Cell: Clinical Trial
Sign up to get notified when there's something new on the CTX001 in Severe Sickle Cell: Clinical Trial page.

Latest updates to the CTX001 in Severe Sickle Cell: Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2. Removed the government funding lapse notice and the previous Revision: v3.4.1.SummaryDifference0.4%

- Check21 days agoChange DetectedA site-wide notice about a lapse in government funding was added, including a statement that the NIH Clinical Center is open and guidance to check cc.nih.gov and opm.gov for updates. The page revision tag was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedThe update adds a glossary toggle display and updates QC-related metadata labels (Last Update Submitted that Met QC Criteria) with revision tag v3.4.0, replacing v3.3.4. Core study content, outcomes, and eligibility criteria remain unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision history shows a new entry Revision: v3.3.4 added and the previous entry Revision: v3.3.3 removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check49 days agoChange DetectedAdded a new Blood Advances publication by Sharma A. et al. detailing improvements in health-related quality of life after exagamglogene autotemcel (Blood Advances, 2025 Dec 23; 9(24):6481-6490). Removed the earlier 'Online ahead of print' entry for the same topic (Blood Advances, 2025 Aug 19; doi: 10.1182/bloodadvances.2025016701).SummaryDifference0.0%

- Check64 days agoChange DetectedAdded a consolidated Locations section listing study sites in California, Illinois, New York, Pennsylvania, Tennessee, and Texas. Removed the separate state Location subsections (California Locations, Illinois Locations, New York Locations, Pennsylvania Locations, Tennessee Locations, Texas Locations) and the HHS Vulnerability Disclosure link.SummaryDifference0.7%

Stay in the know with updates to CTX001 in Severe Sickle Cell: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CTX001 in Severe Sickle Cell: Clinical Trial page.